Skip to main content
SpringerLink
Log in

Increased local cytokine production at culprit superficial femoral artery plaques

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Characterization of local inflammation at culprit superficial femoral artery (SFA) stenosis has not been studied. We hypothesized that arterial cytokine concentrations would be greater at sites of stenosis. Twenty patients with ≥50 % angiographic stenosis of the SFA had blood drawn just proximal to the lesion and from a contralateral site free of disease. A microplate immunoassay was used to determine the concentrations of 42 distinct cytokines and growth factors. Exact conditional logistic analysis was used to compare measures at the two sites with interaction terms describing clinical factors used to identify difference mediators. Interaction terms identified clinical factors that could predict cytokine levels. The concentrations of soluble CD40 ligand (sCD40L; mean 212 and 177 pg/ml, p = 0.01) and tumor necrosis factor beta (TNF-B; mean 16.6 and 15.9 pg/ml, p = 0.04) were increased immediately proximal to areas of stenosis. Factors associated with greater concentrations at sites of stenosis were bilateral ankle-brachial index ≤0.90 (p = 0.04), no statin use (p = 0.02), claudication (p = 0.03), low leukocyte count (p = 0.03), absence of limb ischemia (p = 0.04) and lack of aspirin or clopidogrel therapy (p ≤ 0.06). Greater concentrations of sCD40L and TNF-B at sites of stenosis suggest that these cytokines play a role in the pathogenesis of symptomatic SFA disease. Our results also suggest that statin, aspirin and clopidogrel therapy may attenuate localized inflammation in the SFA, though due to a small sample size and the use of multiple comparisons across groups, these findings can be viewed as hypothesis generating only. In conclusion, selected cytokines are heightened at culprit SFA lesions and inflammation may be modulated by statin and antiplatelet therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Silvestro A, Scopacasa F, Ruocco A, Oliva G, Schiano V, Zincarelli C, Brevetti G (2003) Inflammatory status and endothelial function in asymptomatic and symptomatic peripheral arterial disease. Vasc Med 8(4):225–232

    Article  PubMed  Google Scholar 

  2. Fisman EZ, Benderly M, Esper RJ, Behar S, Boyko V, Adler Y, Tanne D, Matas Z, Tenenbaum A (2006) Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. Am J Cardiol 98(1):14–18

    Article  PubMed  CAS  Google Scholar 

  3. Lee WJ, Sheu WH, Chen YT, Liu TJ, Liang KW, Ting CT, Lee WL (2006) Circulating CD40 ligand is elevated only in patients with more advanced symptomatic peripheral arterial diseases. Thromb Res 118(5):619–626

    Article  PubMed  CAS  Google Scholar 

  4. Aggarwal A, Schneider DJ, Terrien EF, Sobel BE, Dauerman HL (2004) Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques. Am J Cardiol 93(1):6–9

    Article  PubMed  CAS  Google Scholar 

  5. Meru AV, Mittra S, Thyagarajan B, Chugh A (2006) Intermittent claudication: an overview. Atherosclerosis 187(2):221–237

    Article  PubMed  CAS  Google Scholar 

  6. Aggarwal A, Schneider DJ, Terrien EF, Terrien CM Jr, Sobel BE, Dauerman HL (2003) Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting. Am J Cardiol 91(11):1346–1349

    Article  PubMed  CAS  Google Scholar 

  7. Aggarwal A, Schneider DJ, Sobel BE, Dauerman HL (2003) Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting. Am J Cardiol 92(8):924–929

    Article  PubMed  CAS  Google Scholar 

  8. Aggarwal A, Blum A, Schneider DJ, Sobel BE, Dauerman HL (2004) Soluble CD40 ligand is an early initiator of inflammation after coronary intervention. Coron Artery Dis 15(8):471–475

    Article  PubMed  Google Scholar 

  9. Yoshioka T, Funayama H, Hoshino H, Nakamura T, Sugawara Y, Kubo N, Nagata O, Ako J, Ishikawa SE, Kawakami M, Momomura S (2010) Association of CD40 ligand levels in the culprit coronary arteries with subsequent prognosis of acute myocardial infarction. Atherosclerosis 213(1):268–272

    Article  PubMed  CAS  Google Scholar 

  10. Suzuki H, Kusuyama T, Sato R, Yokota Y, Tsunoda F, Sato T, Shoji M, Iso Y, Koba S, Katagiri T (2008) Elevation of matrix metalloproteinases and interleukin-6 in the culprit coronary artery of myocardial infarction. Eur J Clin Investig 38(3):166–173

    Article  CAS  Google Scholar 

  11. Berger JS, Ballantyne CM, Davidson MH, Johnson JL, Tarka EA, Lawrence D, Trivedi T, Zalewski A, Mohler ER (2011) Peripheral artery disease, biomarkers, and darapladib. Am Heart J 161(5):972–978

    Article  PubMed  CAS  Google Scholar 

  12. McDermott MM, Guralnik JM, Corsi A, Albay M, Macchi C, Bandinelli S, Ferrucci L (2005) Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study. Am Heart J 150(2):276–281

    Article  PubMed  Google Scholar 

  13. Pradhan AD, Shrivastava S, Cook NR, Rifai N, Creager MA, Ridker PM (2008) Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk. Circulation 117(6):823–831

    Article  PubMed  Google Scholar 

  14. Shankar A, Li J, Nieto FJ, Klein BE, Klein R (2007) Association between C-reactive protein level and peripheral arterial disease among US adults without cardiovascular disease, diabetes, or hypertension. Am Heart J 154(3):495–501

    Article  PubMed  CAS  Google Scholar 

  15. Fiotti N, Giansante C, Ponte E, Delbello C, Calabrese S, Zacchi T, Dobrina A, Guarnieri G (1999) Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 145(1):51–60

    Article  PubMed  CAS  Google Scholar 

  16. Marnell L, Mold C, Du Clos TW (2005) C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 117(2):104–111

    Article  PubMed  CAS  Google Scholar 

  17. Forte L, Cimmino G, Loffredo F, De Palma R, Abbate G, Calabrò P, Ingrosso D, Galletti P, Carangio C, Casillo B, Calabrò R, Golino P (2011) C-reactive protein is released in the coronary circulation and causes endothelial dysfunction in patients with acute coronary syndromes. Int J Cardiol 152(1):7–12

    Article  PubMed  Google Scholar 

  18. Nishimoto N, Kishimoto T (2006) Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2(11):619–626

    Article  PubMed  CAS  Google Scholar 

  19. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG (2005) C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 112(7):976–983

    Article  PubMed  CAS  Google Scholar 

  20. Ko YG, Jung JH, Park S, Choi E, Joung B, Hwang KC, Ha JW, Choi D, Jang Y, Chung N, Shim WH, Cho SY (2006) Inflammatory and vasoactive factors in the aspirate from the culprit coronary artery of patients with acute myocardial infarction. Int J Cardiol 112(1):66–71

    Article  PubMed  Google Scholar 

  21. André P, Nannizzi-Alaimo L, Prasad SK, Phillips DR (2002) Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106(8):896–899

    Article  PubMed  Google Scholar 

  22. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroczek RA (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391(6667):591–594

    Article  PubMed  CAS  Google Scholar 

  23. Miller DL, Yaron R, Yellin MJ (1998) CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J Leukoc Biol 63(3):373–379

    PubMed  CAS  Google Scholar 

  24. Xu Y, Song G (2004) The role of CD40-CD154 interaction in cell immunoregulation. J Biomed Sci 11(4):426–438

    Article  PubMed  CAS  Google Scholar 

  25. Worm M, Ebermayer K, Henz B (1998) Lymphotoxin-alpha is an important autocrine factor for CD40 + interleukin-4-mediated B-cell activation in normal and atopic donors. Immunology 94(3):395–402

    Article  PubMed  CAS  Google Scholar 

  26. Batuca JR, Amaral MC, Alves JD (2009) Humoral mechanisms of atherogenesis. Ann N Y Acad Sci 1173:401–408

    Article  PubMed  CAS  Google Scholar 

  27. Sanguigni V, Pignatelli P, Lenti L, Ferro D, Bellia A, Carnevale R, Tesauro M, Sorge R, Lauro R, Violi F (2005) Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 111(4):412–419

    Article  PubMed  CAS  Google Scholar 

  28. Pastuszczak M, Kotlarz A, Mostowik M, Zalewski J, Zmudka K, Undas A (2010) Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction. Thromb Res 125(5):382–386

    Article  PubMed  CAS  Google Scholar 

  29. Alber HF, Frick M, Suessenbacher A, Doerler J, Schirmer M, Stocker EM, Dichtl W, Pachinger O, Weidinger F (2006) Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease—a randomized, placebo-controlled study. Am Heart J 151(1):139

    Article  PubMed  Google Scholar 

  30. Chu CS, Lee KT, Lee MY, Su HM, Voon WC, Sheu SH, Lai WT (2006) Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 5:646–650

    Article  Google Scholar 

  31. Han SH, Koh KK, Quon MJ, Lee Y, Shin EK (2007) The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients. Atherosclerosis 190(1):205–211

    Article  PubMed  CAS  Google Scholar 

  32. Azar RR, Kassab R, Zoghbi A, Aboujaoudé S, El-Osta H, Ghorra P, Germanos M, Salamé E (2006) Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 151(2):521.e1–521.e4

    Article  CAS  Google Scholar 

  33. Furman MI, Benoit SE, Barnard MR, Valeri CR, Borbone ML, Becker RC, Hechtman HB, Michelson AD (1998) Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 31(2):352–358

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflicts of interest.

Author information

Authors and Affiliations

  1. College of Medicine, University of Vermont, Burlington, VT, USA

    Cameron W. Donaldson, David J. Schneider, Daniel J. Bertges, Julie E. Adams, Nader Z. Elgharib, Enkhtuyaa L. Mueller, William Prabhu, Taka Ashikaga & Harold L. Dauerman

  2. Division of Cardiology, University of Vermont, Fletcher Allen Health Care, 111 Colchester Ave, Burlington, VT, 05401, USA

    Cameron W. Donaldson

Authors
  1. Cameron W. Donaldson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David J. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel J. Bertges
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Julie E. Adams
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nader Z. Elgharib
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Enkhtuyaa L. Mueller
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. William Prabhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Taka Ashikaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Harold L. Dauerman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cameron W. Donaldson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Donaldson, C.W., Schneider, D.J., Bertges, D.J. et al. Increased local cytokine production at culprit superficial femoral artery plaques. J Thromb Thrombolysis 36, 293–299 (2013). https://doi.org/10.1007/s11239-012-0860-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-012-0860-1

Keywords

Search

Navigation